Quick Verdict
Benitec Biopharma reported FY 2026 EPS of -$0.98 on $0 revenue, as it remains a clinical-stage company without commercial product sales. The annual net loss widened to $45.5 million, but cash nearly doubled to $180.0 million. BNTC shares fell 8.53% in the next trading session after the announcement.
About Benitec Biopharma
Benitec Biopharma Inc. (NASDAQ: BNTC) is a Hayward, California-based clinical-stage biotechnology company developing genetic medicines for life-threatening, genetically defined diseases. The company uses its proprietary “Silence and Replace” DNA-directed RNA interference, or ddRNAi, platform, which combines RNA interference with gene therapy to silence disease-causing genes while delivering functional replacement genes in a single administration. Its lead investigational therapy, BB-301, is being evaluated for dysphagia associated with oculopharyngeal muscular dystrophy (OPMD), a rare inherited neuromuscular condition.
Benitec reported no revenue in either FY 2026 or FY 2025 because it has not commercialized a product. The company’s fiscal-year-end cash position was $180.0 million, while its market capitalization was approximately $382 million as of the reporting period. As a loss-making, pre-revenue biotech, BNTC does not have a meaningful P/E ratio and does not pay a dividend. Benitec was founded in 1995 and operates from Hayward, California.
Top Financial Highlights
- Total revenue was $0 in FY 2026, unchanged from FY 2025, reflecting Benitec’s pre-commercial development stage.
- Net loss attributable to common shareholders widened to $45.5 million, versus a $37.9 million loss in FY 2025.
- Basic and diluted loss per share improved to -$0.98, compared with -$1.05 in FY 2025, largely because the weighted-average share count increased.
- Total operating expenses increased 22.3% year over year to $51.2 million, from $41.8 million.
- Research and development expense rose 27.6% to $23.4 million, compared with $18.3 million a year earlier.
- General and administrative expense increased 18.7% to $27.8 million, from $23.4 million in FY 2025.
- R&D expense growth reflected $6.3 million of higher share-based compensation and $2.2 million of higher payroll, partly offset by a $3.8 million decline in contract manufacturing activity
- G&A expense increased principally because of $2.7 million in higher share-based compensation and $0.8 million in higher payroll.
- Net interest income was $5.6 million, up from $3.3 million in the prior year, partially offsetting operating losses.
- Cash and cash equivalents totaled $180.0 million at June 30, 2026, compared with $97.7 million one year earlier.
- Net cash used in operating activities was $16.5 million in FY 2026, while financing activities generated approximately $99 million, helping build the year-end cash balance.
- Common shares outstanding increased to 34.4 million at June 30, 2026, from 26.3 million a year earlier.
- All six low-dose BB-301 Cohort 1 patients completed 12-month follow-up; the high-dose Cohort 2 was fully enrolled, with three patients treated.
- Benitec expects FDA Type C meeting minutes regarding pivotal-trial design in October 2026 and plans to initiate the BB-301 pivotal study in mid-2027.
- Interim Phase 1b/2a data are scheduled for presentation at the ESGCT Congress in Hamburg from October 27–30, 2026.
Beat or Miss?
Because Benitec is a pre-revenue clinical-stage biotechnology company, the release did not provide Wall Street consensus revenue or EPS estimates, nor did it frame results as a beat or miss. The principal investment focus is therefore cash runway, clinical execution, regulatory progress, trial design, and the future development path of BB-301.
| Metric | Reported | Difference/Analysis |
| Revenue | $0 | N/A; Benitec generated no revenue in FY 2026 or FY 2025. |
| EPS | ($0.98) | N/A; no consensus estimate was stated in the release. Loss per share narrowed from -$1.05. |
| Net loss | -$45.5 million | Loss widened by $7.6 million, or 20.1%, year over year. |
| Operating expenses | $51.2 million | Increased by $9.4 million, or 22.3%, driven by higher R&D and G&A spending. |
| Cash and equivalents | $180.0 million | Increased by $82.3 million, or 84.1%, from the prior fiscal year-end. |
| BB-301 pivotal-study timing | Mid-2027 anticipated | Management reiterated the planned initiation timeline rather than issuing conventional earnings guidance. |
The report’s mixed financial picture—higher operating loss but a substantially stronger cash balance—was paired with operational progress for BB-301. The company’s key near-term value drivers are regulatory feedback, forthcoming clinical data, and progress toward a registrational or pivotal study rather than revenue growth.
What Leadership Is Saying
“This has been an important year of clinical execution for Benitec and for the continued development of BB-301. Over the course of the year, we completed the follow-up of all six patients in Cohort 1 and fully enrolled Cohort 2, while continuing the regulatory interactions required to prepare BB-301 for advancement into a pivotal trial.”
— Jerel A. Banks, M.D., Ph.D., Executive Chairman and Chief Executive Officer
“The consistency and durability of the clinical benefit observed to date, together with the discussions we have had with the FDA regarding pivotal study plans, continue to strengthen our conviction in the potential of BB-301 to meaningfully alter the course of OPMD-related dysphagia.”
— Jerel A. Banks, M.D., Ph.D., Executive Chairman and Chief Executive Officer
Historical Performance
| Category | FY 2026 | FY 2025 | Change (%) |
| Revenue | $0 | $0 | N/M |
| Net loss attributable to shareholders | -$45.5 million | -$37.9 million | Loss widened 20.1% |
| EPS | ($0.98) | ($1.05) | Loss per share narrowed 6.7% |
| Research and development expense | $23.4 million | $18.3 million | 27.60% |
| General and administrative expense | $27.8 million | $23.4 million | 18.70% |
| Total operating expenses | $51.2 million | $41.8 million | 22.30% |
| Interest income, net | $5.6 million | $3.3 million | 69.50% |
| Cash and cash equivalents | $180.0 million | $97.7 million | 84.10% |
N/M = not meaningful because revenue was zero in both periods. Financial figures are for years ended June 30.
Competitor Comparison
A like-for-like revenue, net income, and operating expense comparison is not meaningful for Benitec’s direct therapeutic competitors because BB-301 targets the rare-disease indication of OPMD-related dysphagia, and Benitec describes it as the only disease-modifying genetic medicine currently in clinical development for that use. Most comparable companies are broader clinical-stage gene-therapy developers with different pipelines, indications, fiscal calendars, and commercial status.
| Category | Benitec FY 2026 | Direct OPMD Disease-Modifying Gene-Therapy Comparator | Change/Analysis |
| Revenue | $0 | No directly comparable disclosed peer | Benitec remains pre-revenue. |
| Net income | -$45.5 million | No directly comparable disclosed peer | Development-stage loss reflects BB-301 advancement and corporate costs. |
| Operating expenses | $51.2 million | No directly comparable disclosed peer | Spending increased as BB-301 progressed through Phase 1b/2a and pivotal-trial preparation. |
| Lead-program stage | Phase 1b/2a | No directly comparable program identified | BB-301 is described by Benitec as the only disease-modifying genetic medicine in clinical development for OPMD-related dysphagia. |
For a broader competitive peer set, the most relevant comparison would be against clinical-stage AAV gene-therapy companies rather than direct OPMD peers. That analysis should normalize for each company’s cash runway, number of active trials, pipeline breadth, trial phase, manufacturing commitments, and share dilution—not just reported net losses.
How the Market Reacted?
BNTC closed 8.53% lower on September 15, 2026, the first trading day following the September 14 release, according to StockTitan’s market-tracking data. The session’s relative volume reached 6.3 times the daily average, suggesting elevated investor activity around the results and clinical update.
The reaction indicates that investors placed substantial weight on the larger full-year operating loss, growing expense base, and continued absence of revenue despite the stronger cash position and clinical milestones. Fundamentally, the update reads as operationally constructive—Cohort 1 follow-up completed, Cohort 2 fully enrolled, FDA engagement underway, and a mid-2027 pivotal trial target—but financial risk remains centered on execution, trial outcomes, regulatory alignment, and future dilution risk. Benitec also filed a shelf registration statement that could allow it to offer up to $200 million of securities, a potential long-term financing flexibility that investors may view alongside its existing $180 million cash balance
